MedTrace Logo

A Comparison of Pregabalin (Lyrica®) to Placebo in Pain Relief After Photorefractive Keratectomy (PRK) Surgery

NCT01097577 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2020-10-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy of pregabalin to placebo for postoperative pain control after photorefractive keratectomy.

Conditions

  • Postoperative Pain

Interventions

DRUG

pregabalin

1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.

DRUG

Placebo

1 capsule by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.

Sponsors & Collaborators

  • 59th Medical Wing

    lead FED

Principal Investigators

  • Julie M Meek, PharmD · 59th Medical Wing

  • Charles Reilly, MD · 59th Medical Wing

  • Margaret Bonnie Rosbolt, PharmD, CCRC · 59th Medical Wing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01097577 on ClinicalTrials.gov